Cerenis Therapeutics S.A.

https://www.cerenis.com

Cerenis Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of novel HDL therapies for the treatment of cardiovascular and metabolic diseases. HDL is the primary facilitator of the reverse lipid transport, or RLT, pathway by which excess cholesterol is removed from arteries and is transported to the liver for elimination from the body. Cerenis is developing a portfolio of HDL therapies, including HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients, and HDL elevators for patients with low HDL. Cerenis is well positioned to become the leader in the HDL therapeutic market with a broad portfolio of programs in development. Since its inception in 2005, the company raised €117 million in equity with top tier investors: Sofinnova Partners, HealthCap, Alta Partners, EDF Ventures, Daiwa Corporate Investment, TVM Capital, Orbimed, IRDI/IXO Private Equity and the FSI (Fund for Strategic Investment). €10.7 million were also provided by OSEO, the French agency for innovation, to support the development of CER-001. About CER-001 CER-001, a complex of recombinant human ApoA-I and phospholipids, is being developed for the treatment of patients with acute coronary syndrome. CER-001 is designed to mimic pre-beta HDL, the "good" cholesterol, to promote the removal of excess cholesterol and other lipids from artery walls and enhance reverse lipid transport. *

	Start	2005-03-24 established
	End	2019-08-29 renamed
	Group	Abionyx (Group)
	Today	Abionyx Pharma S.A. (Euronext Paris: ABNX)
	Successor	Abionyx Pharma S.A. (Euronext Paris: ABNX)
	Industry	cardiovascular drug
	Industry 2	CER-001 (Cerenis)
	Person	Dasseux, Jean-Louis (Cerenis Therapeutics 200508 CEO + Pres)
	Person 2	Tupin, Cyrille (Abionyx 201909– CEO before Deputy CEO + CFO of predecessor Cerenis Therapeutics)

	Region	Labège
	Country	France
	Street	265 Rue de la Découverte BP 87519
	City	31675 Labège
	Tel	+33-5-6224-9706
		Address record changed: 2020-12-02

Basic data	Employees	n. a.
	Currency	EUR
	Cash	21,500,000 (2017-05-31)

		* Document for »About Section«:

		Record changed: 2024-02-12